Fate Therapeutics Inc (FATE) income statement
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3029% below fair value
$0.92−0.09 (-9.01%)
Close on Nov 20, 2026Market cap $110.12MP/E –Yield –
Fate Therapeutics Inc financial ratios
See a number that looks wrong?